Copper-dependent amino oxidases in cardiovascular disease

Applied bioinorganic chemistry sits where coordination chemistry, molecular biology and medicine meet. At the 16th International Symposium on Applied Bioinorganic Chemistry in Ioannina, Greece, in June 2023, the University of Ioannina brought together an international community to examine how metal-based systems can be applied to biological problems.

Copper-dependent amino oxidases catalyse the oxidation of amines and provide a direct link between enzyme chemistry and vascular health. Their activity can affect extracellular-matrix organisation, redox balance and inflammatory responses, making them relevant to hypertension, atherosclerosis, aneurysm and other forms of cardiovascular disease.

For Australian researchers, this topic has familiar clinical and logistical dimensions. Sydney and Melbourne host substantial cardiovascular research programmes, while Australia’s complementary-medicines market includes products marketed around copper. Moving specimens between Australian laboratories and Greece also involves customs, biosecurity and packaging rules that must be addressed before travel.

The meeting’s value extended beyond presentations. Young scientist travel awards, poster prizes, scholarships and clear application requirements supported participation and career development. For laboratories studying vascular bioinorganic chemistry, the scientific questions are substantial: can we control damaging oxidase activity without disrupting the protective functions of copper enzymes?

Copper coordination in vascular chemistry

In lysyl oxidase, two copper ions participate directly in molecular oxygen activation, enabling covalent crosslinking of collagen and elastin. The enzyme is essential for tensile strength, yet excessive or misplaced activity can stiffen arteries and contribute to vascular remodelling. The cardiovascular challenge is controlling chemistry that is protective during development and harmful when dysregulated.

Other amine oxidases broaden the picture. Vascular adhesion protein-1, also called semicarbazide-sensitive amine oxidase or AOC3, participates in leukocyte recruitment and endothelial dysfunction. Diamine oxidase contributes to mucosal histamine metabolism, while D-amino acid oxidase connects amino acid turnover with redox conditions. These enzymes have different roles, yet each offers a tractable way to investigate copper-dependent regulation.

Matrix crosslinking and arterial stiffness

Copper deficiency is not a simple explanation for cardiovascular disease. Altered metal availability can affect the maturation of copper-dependent oxidases, while inflammation can increase oxidase-derived products that impair nitric oxide signalling. Separating inadequate copper status from excessive enzyme activity is essential before nutritional or pharmacological strategies can be justified.

Melbourne and Sydney provide strong settings for pairing vascular imaging with biochemical assays. An Australian collaboration might use well-characterised patient cohorts to test whether collagen crosslinking or oxidative products track with arterial stiffness. Such work would connect population-level cardiovascular patterns with the molecular mechanisms observed in laboratory models.

Oxidative stress and vascular inflammation

Reactive oxygen species generated during oxidase reactions can amplify oxidative stress, endothelial dysfunction and inflammation. These pathways feed one another: vessel-wall damage recruits immune cells, activated cells release more reactive species, and matrix remodelling changes blood flow. This feedback offers possible intervention points, although broad antioxidant strategies have not consistently translated into cardiovascular benefit.

AOC3 and related enzymes may offer a more selective entry point. The experimental question is whether inhibiting an enzyme can reduce vascular adhesion without suppressing wider immune function. That requires careful inhibitor design, appropriate models and endpoints that measure vessel behaviour rather than enzyme activity alone.

Selective inhibitors and chemical probes

The copper centre provides a rational handle for inhibitor discovery. Molecules can bind active-site copper, obstruct substrate access or exploit differences between enzymes such as lysyl oxidase and AOC3. Selectivity matters because members of this biochemical family contribute to metabolism, tissue repair and defence. Chemical probes must also distinguish specific enzyme inhibition from copper chelation or general oxidative effects.

An applied programme can move from coordination chemistry to cellular assays, animal models and candidate profiling. Toxicity, solubility and exposure are decisive constraints for a cardiovascular drug used over many years. A related copper and neurodegeneration review shows how metal-complex chemistry can illuminate disease mechanisms beyond the vasculature, while reinforcing the need for rigorous biological testing.

Biomarkers and clinical translation

Potential readouts include amine-oxidation products, extracellular-matrix fragments, vascular adhesion markers and measures of arterial stiffness. No single marker is likely to capture the entire pathway. A useful diagnostic strategy may combine biochemical evidence with imaging and clinical phenotyping, particularly when copper status and enzyme activity differ between people.

The June 2023 meeting is also a useful record of the field at that point. The symposium programme preserves sessions spanning applied bioinorganic chemistry and biomedical research, helping investigators trace connections between enzyme design, analytical methods and disease models. Poster discussions can reveal which approaches are mature enough for larger, independently funded studies.

Australian research and regulatory realities

Australian investigators should plan the practical side of international work early. Human-derived cells, tissue and blood samples may require import permits, biosecurity inspection and compliant packaging before entry to Australia, with the Department of Agriculture, Fisheries and Forestry providing the applicable conditions. Couriers must also receive accurate declarations for biological material, dry ice and dangerous goods.

The local market deserves equal caution. Copper-containing supplements are part of Australia’s complementary-medicines sector, but regulatory listing is not proof that extra copper prevents or treats cardiovascular disease. The Therapeutic Goods Administration applies quality and advertising rules; permission to sell a product is not a clinical recommendation. Trials, not shelf claims, should guide practice, and consumers with cardiovascular disease should discuss supplementation with their clinician.

Build connections through the symposium

The University of Ioannina and Zita Congress & Event Management, the official symposium secretariat, supported registration, accommodation and abstract-related enquiries. Young scientist travel awards, poster prizes and scholarships recognised early-career work and widened access to the meeting. These mechanisms are particularly valuable to students who need scientific exchange and practical support to attend a gathering in Ioannina.

Begin by reviewing the archived programme and the award, scholarship and poster-prize information on the official site, then identify researchers working on copper enzymes, vascular biology or bioinorganic therapeutics. Contact Zita Congress & Event Management for registration, accommodation and abstract-related enquiries, and use the Ioannina meeting as the foundation for your next Australian-led study or conference submission.